Winton Group LTD Chemo Centryx, Inc. Transaction History

Winton Group LTD

$1.31 Billion
Q3 2024

Shares

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 10, 2022	SELL	$22.17 - $51.8 $67,485 - $157,679	-3,044 Reduced 10.86%	24,993 $1.29 Million
Q2 2022 Aug 10, 2022	BUY	$15.36 - $27.51 $74,142 - $132,790	4,827 Added 20.8%	28,037 $695,000
Q1 2022 May 11, 2022	SELL	$22.22 - $39.12 $262,662 - $462,437	-11,821 Reduced 33.74%	23,210 $582,000
Q4 2021 Feb 10, 2022	BUY	$18.38 - $40.5 $377,304 - $831,384	20,528 Added 141.54%	35,031 $1.28 Million
Q3 2021 Oct 28, 2021	SELL	$13.18 - $19.83 $276,648 - $416,231	-20,990 Reduced 59.14%	14,503 $248,000
Q2 2021 Aug 10, 2021	BUY	$9.59 - $50.88 $187,858 - $996,688	19,589 Added 123.17%	35,493 $475,000
Q1 2021 Jul 21, 2021	SELL	$49.53 - $68.4 $19,663 - $27,154	-397 Reduced 2.44%	15,904 $815,000
Q4 2020 Feb 12, 2021	SELL	$47.25 - $65.16 $2.43 Million - $3.35 Million	-51,420 Reduced 75.93%	16,301 $1.01 Million
Q3 2020 Oct 30, 2020	BUY	$46.35 - $61.69 $2.91 Million - $3.87 Million	62,726 Added 1255.78%	67,721 $3.71 Million
Q2 2020 Aug 05, 2020	SELL	$38.58 - $65.07 $513,885 - $866,732	-13,320 Reduced 72.73%	4,995 $287,000
Q1 2020 May 11, 2020	SELL	$32.73 - $50.78 $2.25 Million - $3.49 Million	-68,633 Reduced 78.94%	18,315 $736,000
Q4 2019 Feb 13, 2020	BUY	$6.81 - $39.55 $486,976 - $2.83 Million	71,509 Added 463.17%	86,948 $3.44 Million
Q3 2019 Nov 08, 2019	BUY	$6.47 - $8.96 $99,890 - $138,333	15,439 New	15,439 $105,000
Q2 2019 Jul 08, 2019	SELL	$8.31 - $14.85 $105,345 - $188,253	-12,677 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$10.01 - $13.89 $126,896 - $176,083	12,677 New	12,677 $176,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Winton Group LTD with notifications on news.